Monday, May 13, 2024 7:27:44 PM
CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.
Recent NTLA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 09:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 12:45:08 PM
- Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 11/07/2024 12:30:00 PM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 11/05/2024 09:01:00 PM
- Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 • GlobeNewswire Inc. • 10/31/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2024 08:59:28 PM
- Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) • GlobeNewswire Inc. • 10/24/2024 12:01:00 PM
- Intellia Therapeutics Announces New Date for Upcoming Investor Webcast • GlobeNewswire Inc. • 10/10/2024 11:30:00 AM
- Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) • GlobeNewswire Inc. • 10/07/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2024 09:29:43 PM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 10/03/2024 08:01:00 PM
- Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions • GlobeNewswire Inc. • 10/01/2024 11:30:00 AM
- Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting • GlobeNewswire Inc. • 09/12/2024 11:30:00 AM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/03/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:06:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:45:09 AM
- Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 08/08/2024 11:30:00 AM
- Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:17:08 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:13:01 PM
- Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/24/2024 08:01:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/18/2024 08:03:06 PM
- Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm • PR Newswire (US) • 07/02/2024 04:53:00 PM
- Intellia Therapeutics Announces CFO Transition • GlobeNewswire Inc. • 06/26/2024 11:30:00 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM